clinical trial · NCT06400511
A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
Famy Life Sciences, a Viatris Company·phase3·terminated·n = 477
BlepharitisPimecrolimus 0.3% Ophthalmic OintmentPlacebo Ophthalmic Ointment
brief summary
The objective of this study is to determine the efficacy and safety of Pimecrolimus 0.3% (MR-139) Ophthalmic Ointment.
started
Apr 22, 2024
primary completion
Sep 9, 2025
completion
Oct 15, 2025
last updated
Jan 7, 2026
detailed description
The study is designed to evaluate Pimecrolimus 0.3% Ophthalmic Ointment in subjects with blepharitis to complete resolution (score = 0 on grading scale of 0-4) for eyelid debris after BID use at Week 6 in the Study Eye.
official title
A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol